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Four recombinant, diagnostically useful Epstein-Barr virus (EBV) proteins representative of the viral capsid
antigen (pl5O), diffuse early antigen (p54), the major DNA-binding protein (pl38), and the EBV nuclear
antigen (p72) (W. Hinderer, H. Nebel-Schickel, H. H. Sonneborn, M. Motz, R. Kuhbeck, and H. Wolf, J. Exp.
Clin. Cancer Res. 7[Suppl.]:132, 1988) were used to set up individual enzyme-linked immunosorbent assays
(ELISAs) for the qualitative and quantitative detection of immunoglobulin M (IgM) and IgG antibodies. In
direct comparison with results obtained by standard immunofluorescence or immunoperoxidase assays, it was
then shown that the recombinant EBV ELISAs provide the means for specific and sensitive serodiagnosis of
infectious mononucleosis (IM) caused by EBV. The most useful markers in sera from such patients proved to
be IgM antibodies against p54, pl38, and pl5O. Additional positive markers for recent or ongoing IM
apparently were IgG antibodies against p54 and pl38. In contrast, anti-p72 IgG had a high preference for sera
from healthy blood donors and, therefore, can be considered indicative of past exposure to the virus.
Altogether, the individual ELISAs proved to be as specific and at least as sensitive for the diagnosis of IM as
the currently available standard techniques are. Moreover, our findings suggest that, by combining individual
test antigens, a workable ELISA system consisting of three assays (IgM against p54, pl38, and plSO; IgG
against p54 and pl38; and IgG against p72) can be established for the standardized rapid diagnosis of acute
EBV infections.
The syndrome infectious mononucleosis (IM) comprises
mainly fever, pharingitis, and cervical lymphadenopathy but
may be complicated by splenomegaly, hepatitis, and myal-
gia, as well as headache and further unspecific symptoms (2).
The causative agent of IM is Epstein-Barr Virus (EBV);
however, other pathogens, mainly cytomegalovirus but also
adenovirus, rubella virus, human immunodeficiency virus,
and Toxoplasma gondii, can cause a similar syndrome. At
present, testing for heterophil antibodies is frequently used
to relate IM to EBV infection. These so-called Paul-Bunnell
tests are simple and rapid; yet, the test results are not
necessarily conclusive, because heterophil antibodies can
also be induced by viruses other than EBV and because their
incidence among patients with IM is, at most, 90% (3). In
particular, young children (<4 years old) often lack a het-
erophil antibody response (22).
The uncertainties of the Paul-Bunnell reaction can be
overcome by specific EBV serodiagnosis (10). To date this is
predominantly performed by indirect immunofluorescence
(IF) or immunoperoxidase (IP) staining of EBV-infected
cells. Standard assays make use of fixed cells derived from
selected EBV-infected cell cultures which specifically ex-
press EBV-associated antigens such as the viral capsid
antigens (VCAs), a set of early antigens (EAs, which can be
subdivided into EA diffuse and EA restricted), and EBV
nuclear antigens (EBNAs); these antigens correspond to the
late lytic phase, the early lytic phase, and the phase of
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latency of EBV infections, respectively. Qualitative and
quantitative determinations of immunoglobulin M (IgM)
and/or IgG antibodies against individual antigens or combi-
nations of these antigens then allows discrimination among
primary, past, and reactivated EBV infections. However, IF
assays are time-consuming and are not suitable for large-
scale testing, and because of variability of antigen-producing
cells as weil as subjective reading of results, they are also
difficult to standardize.
Various attempts have been made to facilitate the specific
serodiagnosis ofEBV infections by developing microdilution
plate assays based either on native antigens purified from
EBV-infected cells (19) or on synthetic peptides selected
empirically or by computer analysis from the amino acid
sequences of presumptively relevant EBV-associated anti-
gens (4, 5, 16). The complexity of the phase-specific anti-
gens, as well as the lack of suitable culture systems for bulk
production, however, do not support their use for routine
diagnosis.
By using recombinant DNA technology, defined EBV-
specific antigens can be produced in sufficient amounts.
Recently, suitable EBV polypeptides were selected by com-
puter-assisted predictions of putative immunogenic regions
as well as by immunoprecipitation and Western immunoblot
experiments with defined EBV sera (18, 24). The antigens
were cloned, expressed in Escherichia coli, and purified to
apparent homogeneity (11). These recombinant proteins
showed excellent reactivities when they were included in
Western blots or enzyme-linked immunosorbent assays
(ELISAs) in preliminary diagnostic studies. They have now
been used to set up ELISAs for the diagnosis of EBV-
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associated diseases. In this study we showed that, in direct
comparison with results obtained by standard IF assays,
these recombinant EBV ELISAs provide the means for the
specific, sensitive, and rapid serodiagnosis of IM or, in more
general terms, of the early acute phase of EBV infection.
MATERIALS AND METHODS
Sera. A total of 75 serum specimens were collected from
57 patients who presented with clinical symptoms suggestive
of IM. The symptoms commonly found in these patients
included fever, tonsillar enlargement, lymphadenopathy,
splenomegaly andlor hepatomegaly, hepatitis, rash, and
atypical blood lymphocytes. Two to four follow-up serum
specimens were available from 13 of the patients. Age, sex,
and the time at which the samples were collected are
specified in Tables 2 and 3. In addition, 161 serum specimens
were obtained from asymptomatic, healthy blood donors
(ABDs).
Standard laboratory diagnosis. Serologic diagnosis of
acute EBV infection was performed by the standard meth-
ods (10, 20) routinely used in our laboratory. IgG antibodies
to VCA and EA were determined by indirect IF on the basis
of slides prepared from antigen-producing P3HR1 cells in
our laboratory and by use of slides purchased from Gull
Laboratories, Inc. (Salt Lake City, Utah), respectively. IgM
antibodies to VCA were assayed by indirect IP staining on
slides available from Savyon Diagnostics Ltd. (Beer Sheva,
Israel). To remove unspecific reactivities as a result of the
presence of rheumatoid factors and antigen-specific IgG, the
sera were preadsorbed as specified by the manufacturer of
the test system. Finally, antibodies against EBNA were
determined by anticomplement IF (ACIF) on slides pur-
chased from Gull Laboratories. Sera from patients with a
presumptive clinical diagnosis of IM were initially tested for
IgM antibodies to VCA (VAC-IgM). If the result was nega-
tive or inconclusive, a second serum specimen was re-
quested. For the positive diagnosis of acute EBV infection,
suggestive clinical symptoms must be matched by serologic
parameters indicative of a current or recent acute EBV
infection. These parameters consisted of a combination of
the presence of VCA-IgM, the absence or presence at very
low titers of antibodies to EBNA only, or the presence of
IgG antibodies to VCA (VCA-IgG) and IgG antibodies to
EA.
Recombinant EBV antigens. The selected EBV genomic
regions were cloned and expressed in E. coli JM109 by using
standard pUC vectors. All four clones expressed stable
proteins without fused bacterial proteins (see Table 1). The
recombinant antigens were produced at a preparative scale
in L broth starting with a culture volume of 6 liters and
inducing synthesis by treatment with 1 mM isopropyl-,3-D-
thiogalactopyranoside over a period of 4 h. Cells were
harvested by centrifugation; after lysis of cells with lyso-
zyme and subsequent sonification, the antigens were purified
either from the supernatant (for p54 and p72) or from the
insoluble sediment (for p138 and piS0). Purification of solu-
ble proteins consisted of fractionation with ammonium sul-
phate, ion-exchange chromatography, and a final gel chro-
matography. The insoluble protein aggregates (inclusion
bodies) of p138 and plS0 were purified by differential wash-
ing and centrifugation with increasing concentrations of
detergents and chaotropic reagents at different pH values.
The average yields of the apparently homogeneous antigens
ranged from 8 mg (p72) to 240 mg (pl38) per preparation.
Purification was monitored by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis and followed by
Coomassie staining or by Western blotting under standard
conditions. For Western blotting, well-defined sera were
used, i.e., those that were either negative or positive for the
individual EBV-associated antigen, a serum specimen that
recognized E. coli proteins, as well as two monoclonal
antibodies directed against p54 and p138. The final purity of
the recombinant polypeptides, as calculated from gels and
blots, was near 100%, except for plS0, which was obtained
at about 95% purity.
Western blots. Proteins were separated by discontinuous
gel electrophoresis by the method of Laemmli (13) and
transferred onto membranes (Immobilon; Millipore Corp.,
Bedford, Mass.) by using a semidry blotting technique (12).
The blocking solution contained 10 mg of bovine serum
albumin per ml in phosphate-buffered saline. Blots were cut
into strips (5 mm), each of which was incubated in 2.5 ml of
serum diluted 1:50 in phosphate-buffered saline with 1 mg of
bovine serum albumin per ml for 4 h at room temperature.
This was followed by washing (four times) with 5 ml of
phosphate-buffered saline supplemented with 0.1% Tween
80. Polyclonal rabbit anti-human IgG or IgM conjugated with
horseradish peroxidase (Dako, Glostrup, Denmark) was
used as revealing antibody (1.5 h, room temperature). Stain-
ing of strips was performed with 3,3'-diaminobenzidine. Sera
from blood donors which were ELISA positive were
retested by this Western blot method by using strips with 100
ng of the corresponding purified antigen. The appearance of
antigen-specific bands was defined as confirmation of an
antigen-specific ELISA reaction.
ELISA procedure. Polystyrene microdilution plates (96-
well; Nunc) were coated with the purified antigens at the
concentrations specified in Table 1. Identical plates were
used for IgG and IgM testing. Murine monoclonal antibod-
ies, anti-human IgG (Biotest AG, Offenbach, Federal Repub-
lic of Germany) and anti-human IgM (Janssen, Beerse,
Belgium), both of which were conjugated with horseradish
peroxidase, served as second antibodies. Sera were diluted
1:21 and allowed to react with the antigens at 40°C for either
30 (IgG) or 60 (IgM) min. This was followed by incubation
with the second antibody at 40°C for 30 min and reaction
with the substrate (1,2-phenylenediamine) at room tempera-
ture for 15 min. All reagents were used in standard volumes
of 100 ,ul. The optical densities (ODs) at 492 and 620 nm were
measured. Sera were always assayed in duplicate; and
blank, negative, as well as positive control sera were in-
cluded on each plate.
To avoid false-positive results in the IgM determinations
because of the presence of rheumatoid factors (8), sera were
treated overnight at 2 to 8°C with a polyclonal goat anti-
human IgG Fc serum.
Frequencies of antibodies in sera from patients with IM. For
calculation of the positive rates of the recombinant ELISAs,
only VCA-IgM-positive sera were used, i.e., the serum
specimens described in Table 2, with the exception of the
serum specimen from patient 2, together with the first
VCA-IgM-positive serum specimens from the serial samples
listed in Table 3. The total number of serum specimens
included was 33.
RESULTS
Cutoif values of ELISAs. Serum specimens from 34 pa-
tients with a presumptive clinical and confirmed laboratory
diagnosis ofIM as well as serum specimens from 161 healthy
blood donors were used to analyze the reactivities of the
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TABLE 1. Characteristics of recombinant EBV antigens used in this study
Antigen Reading frame Classification Construction Size (Mr [kilodaltons]) Concn (i>g/ml) in
of expressed protein coating solution
p54 BMRF1 EA (diffuse) Whole coding region 52, 47 1
p138 BALF2 EA (major DNA-binding protein) Fusion of two selected sections 39 1
pl50 BcLF1 VCA Fusion of two selected sections 47, 22 10
p72 BKRF1 Nuclear antigen (EBNA-1) C-terminal part (42.7%) 46 0.25
four recombinant EBV antigens by a diagnostic ELISA. which was present in sera from all but one patient and which
Thereby, individual antigens were used for coating micro- gave rise to high ODs in most cases, was anti-pl38-IgM. This
dilution plates in concentrations determined earlier (11) and was followed by anti-p54-IgM, which was negative in sera
as specified in Table 1. The cutoff values were set at ODn + from only three patients. The prevalence, and, hence, the
0.1, where ODn is the OD recorded by use of a control diagnostic significance of the IgM antibodies that react with
human serum which proved to be negative for antibodies the recombinant piS0 protein, was considerably lower. In
against all EBV-associated antigens in standard IF tests as one case (patient 5), however, from whose serum all other
well as against the recombinant antigens in Western blots. markers were absent, anti-p150-IgM proved to be indicative
The ODs of this serum specimen varied from 0.000 to 0.051 for primary EBV infection. Finally, anti-p72-IgM evidently
for IgG assays and from 0.001 to 0.116 for IgM assays with failed to contribute substantially to the diagnosis of IM.
the four antigens in different series of experiments. Sera that Significance of IgG antibodies. The diagnostic significance
were reactive in the range of an OD cutoff of +0.05 were of IgG antibodies against the different recombinant proteins
considered equivocal. coincided with that of IgM antibodies (Tables 2 and 3).
Significance of IgM antibodies. Concerning the frequency Anti-p138-IgG and anti-p54-IgG were highly prevalent, and
and diagnostic significance of antibodies against individual at least one of these markers was present in serum speci-
antigens (markers), the data in Tables 2 and 3 indicate that mens from 32 of 34 patients. In contrast, the incidence of
marker combinations as well as relative intensities differed anti-pl50-IgG was low and anti-p72-IgG was absent in 30 of
considerably among patients. The most sensitive marker, 34 serum specimens from patients with confirmed IM. The
TABLE 2. Comparison of EBV serological parameters determined by standard techniques and recombinant ELISAs in sera from 25
patients with confirmed recent or acute EBV infection
IFb ELISA ODC
Patient Age (yr) Sexa VA VC- EN- A-p54 pl38 piSO p72 Rd
no. VCA- VCA- EBNA- EA- p54pl3pl0p
IgG IgM Ig IgG IgG IgM IgG IgM IgG IgM IgG IgM
1 2 M <10 + - 10 - - + + + - - - +
2 2 F <10 ± - >40 - + ++ ± + - - - +
3 2 M <10 + - 10 + + - + - + - - +
4 5 F 640 + - >160 + + + + + + - - +
5 6 M 160 + - <10 - - - + - + - - +
6 9 F 40 + - 640 + + + + + - - - + +
7 10 M 160 + - 640 - + + + ± + - + +
8 il M 160 + - 40 - - ++ +++ - + - - +
9 14 F 640 + - 160 + + + + - + - - +
10 15 F 160 + - 160 + +++ + +++ - + - - +
il 15 F 10 + - 10 + + + + - + - + +
12 16 F 160 + - 40 + + ++ - + - + +
13 16 M 160 + - >40 ± + + + + - - + +
14 18 M 160 + - 80 ++ ++ + + + + - + +
15 19 M 40 + - 10 - + + ++ ± + - - +
16 20 F 160 + - 40 + + + ++ ± + - - +
17 21 M 160 + - 10 - - + - - - - -
18 21 M 640 + - 10 + + + + + ± + - - +
10 21 M 160 + - 40 + + + +++ ± + - + +
20 21 M 40 + - 40 ++ + +++ +++ ± + - + +
21 21 M 160 + - 10 + +++ ++ + - + +
22 22 M 160 + - 40 + +++ +++ ++ ± + - + +
23 24 M 40 + + 160 ± + + +++ +
_
++ - +e
24 27 M 160 + - 40 + +++ + +++ + + ± + +
25 32 F 160 + - 40 +++ +++ +++ +++ ± ± - - +
a M, Male; F, female.
b Interpretation of standard IF results: VCA-IgG, IgG antibodies against viral capsid antigen (positive, -1:10);VCA-IgM, IgM antibodies against VCA
(positive, 21:64; +, 1:32); EBNA-Ig, antibodies against EBNA (positive, >1:10; + weak fluorescence, 1:10); EA-IgG, IgG antibodies to EA (positive, -1:10).
c Interpretation of ELISA results: -, OD < OD cutoff- 0.05; +, OD = OD cutoff + 0.05; +, OD > OD cutoff + 0.05 to 1.0; + +, OD = 1.00 to 2.00; +++,
OD > 2.00.
d R, Laboratory diagnosis according to ELISA results: +, acute EBV infection; -, no evidence for acute EBV infection.
' Possible reactivation.
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TABLE 3. Time course of serological parameters in patients with confirmed acute infection as determined by current standard diagnostic
technique and recombinant ELISA
IFb ELISA ODC
Patient and Age Date
serum (yr) Sexl (day.mo.yr) VCA- VCA- EBNA- EA- P pl38 pl50 p72
sample IgG IgM Ig IgG IgG IgM IgG IgM IgG IgM IgG IgM
26
1 4 F 4.5.88 160 - - <10 0.008 0.005 0.038 0.053 0.149 0.003 0.003 0.008
2 4 F 5.5.88 160 + - <10 0.028 0.029 0.109 0.387 0.404 0.045 0.013 0.054
3 4 F 14.5.88 1,280 + - 160 0.340 0.148 0.815 0.145 0.360 0.105 0.164 0.040
4 4 F 27.5.88 1,280 + - >160 0.458 0.131 0.548 0.074 0.227 0.088 0.086 0.040
27
1 6 F 30.8.88 160 + - 40 0.032 0.265 0.214 0.353 0.132 0.507 2.588 0.177
2 6 F 17.10.88 160 + + 40 0.024 0.208 0.189 0.234 0.116 0.388 2.617 0.127
28
1 13 F 10.3.89 160 ± - 10 2.889 0.167 2.488 2.383 0.269 0.110 0.004 0.214
2 13 F 16.3.89 640 + - 40 2.645 0.200 2.058 1.445 0.213 0.122 0.009 0.072
3 13 F 3.4.89 640 + - 40 2.442 0.116 0.767 0.737 0.200 0.095 0.005 0.144
29
1 12 F 15.3.88 <10 + - <10 0.040 0.212 0.533 0.947 0.148 0.194 0.023 0.296
2 12 F 25.11.88 40 + - <10 0.059 0.625 1.085 1.008 0.193 0.178 0.031 0.361
3 12 F 5.12.88 160 + - 40 0.304 1.836 1.837 1.676 0.155 0.252 0.023 0.131
30
1 15 M 25.8.88 160 + - <10 0.678 0.047 0.107 0.078 0.064 0.052 1.740 0.039
2 15 M 12.9.88 160 + 40 0.300 0.382 0.100 0.144 0.048 0.175 1.633 0.143
31
1 22 F 24.5.88 <10 + - <10 0.028 0.049 0.153 0.086 0.144 0.069 0.114 0.085
2 22 F 1.6.88 160 + - 40 0.361 0.783 0.714 0.884 0.118 0.111 0.009 0.009
32
1 25 F 10.5.88 160 + - 10 0.380 0.452 1.032 0.805 0.273 0.189 0.000 0.091
2 25 F 30.8.88 160 + + 40 0.051 0.102 0.129 0.179 0.191 0.071 0.249 0.051
3 25 F 17.2.89 160 - + 40 0.032 0.050 0.085 0.193 0.160 0.081 2.179 0.049
33
1 25 F 16.3.88 40 + - 40 0.042 0.517 0.468 0.915 0.189 0.152 0.039 0.094
2 25 F 18.3.88 160 + - 10 0.146 0.283 1.008 1.227 0.146 0.183 0.076 0.158
34
1 26 M 26.5.88 <10 - - <10 0.058 0.518 0.370 0.275 0.394 0.058 0.042 0.020
2 26 M 3.6.88 640 + - 80 1.406 2.118 1.208 2.475 0.460 0.240 0.049 0.036
a F, Female; M, male.
b See footnote b of Table 2 for explanations.
C OD at 492 and 620 nm by ELISA. See footnote c of Table 2 for explanations.
latter finding correlates excellently with the results of the
standard ACIF test for EBNA (Tables 2 and 3). Exceptions
were four patients, for whom EBNA ACIF values were
either weakly positive (patients 23 and 30) or showed sero-
conversion in EBNA ACIF (patients 27 and 32). In sera from
these patients, the p72-IgG ELISA was already positive in
the first serum sample and, hence, proved to be of increased
sensitivity.
Follow-up studies and seroconversion. The specificity and
diagnostic significance of IgM and IgG antibodies against
individual markers were underlined by their dynamic varia-
tion with the time of infection, as was evident for those
patients from whom multiple serum specimens were avail-
able (Table 3). The panel of serum specimens from patient 32
represents an excellent example of such a course. It shows,
in full agreement with IF and IP staining results, serocon-
version to anti-p72-IgG in parallel with declining IgM anti-
bodies to the other antigens. Moreover, the initial serum
samples from five of nine patients with follow-up panels
(Table 3) were not yet positive by IP staining of VCA-IgM.
Three of these serum samples, however (those from patients
28, 29, and 34), were clearly IgM positive with the recombi-
nant antigens.
Comparative reactivity in sera from patients with IM and
ABDs. The reactivities of the recombinant antigens with sera
from a control group of 161 apparently healthy blood donors
was also investigated. All positive ELISA readings were
confirmed by Western blotting. Figure 1 compares the prev-
alence of IgM and IgG antibodies to the four recombinant
EBV-encoded antigens in sera from ABDs with those in sera
from the 33 patients with confirmed IM. With the exception
of low ODs against p138 in only 8% of the samples, no
significant IgM reactivities with the recombinant antigens
were detected in the sera from ABDs. On the contrary, most
sera from patients with IM contained IgM antibodies to p54,
p138, and piS0 (see above). IgG antibodies to p54 and pl38
J. CLIN. MICROBIOL.
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FIG. 1. Prevalence of IgG and IgM antibodies directed against different recombinant EBV antigens in sera from ABDs (_) (n = 161) and
patients with acute, serologically confirmed EBV infection (EU) (n = 33). Negative (neg), OD < OD cutoff - 0.05; equivalent (equiv), OD
= OD cutoff + 0.05; positive (pos), OD > OD cutoff + 0.05.
were also strongly increased in sera from patients with IM.
The incidence of anti-p150-IgG, however, was low and quite
similar in sera from both patients with IM and ABDs.
Finally, anti-p72-IgG seemed to be a useful marker for a past
EBV infection, as 84% of sera from ABDs but only 9% of
sera from patients with acute IM turned out to be positive for
this marker. The mean absorption values in sera from ABDs
were as follows: p72-IgG, 1.324; p54-, p138-, and pl50-IgG,
0.129 to 0.169; p72-, p54-, pi38-, and p150-IgM, 0.016 to
0.103.
Reactivities of sera from patients with IM negative by
VCA-IgM-IP. We tested 27 serum specimens from 23 pa-
tients who presented with IM-like symptoms, but these were
found to be negative for anti-VCA-IgM by standard methods
(data not shown in detail). Although they were requested,
second serum specimens were available for only four pa-
tients, and these sera still proved to be negative for anti-
VCA-IgM. This was also confirmed by recombinant ELISA.
On the other hand, 3 of the remaining 19 patients were found
by ELISA to have acute EBV infections. This diagnosis
could subsequently be supported by additional extended IF
assays (negative anti-EBNA and positive anti-VCA-IgG for
all three patients and positive anti-EA antibodies for two
patients).
DISCUSSION
The antigen complexes VCA, EA, and EBNA which form
the basis ofthe classical IF and IP staining assays for specific
laboratory diagnosis of acute EBV infections are not well
defined at the protein level. Despite this situation, the
recombinant proteins used in the present study were se-
lected to match these groups of antigens as much as possible.
They do not necessarily represent, however, the predomi-
nant components of the VCA, EA, and EBNA antigen
complexes. This was certainly true for the EA pl38 (reading
frame BALF2, major DNA-binding protein). This antigen is
not expressed in chemically induced Raji cells (1),which are
often used for EBV EA assays, but is present in significant
amounts in Raji cells superinfected with EBV from P3HR1
cells (10). Hence, the immunologic response to pl38 does
not contribute to anti-EA readings in some IF assays.
According to the results of the present study, however,
antibodies to a recombinant, truncated version of p138 (18)
form a powerful marker for acute EBV infection.
The classical EA complex consists of two components:
diffuse (EA-D) and restricted (EA-R). Of these, the EA-R
component BORF2 (p85) is part of a ribonucleotide reduc-
tase (6), whereas the EA-D component BMRF1 (p54) is
related to an EBV-specific DNA polymerase (14). The
bo-
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recombinant p54 used in this investigation comprises the
complete amino acid sequence specified by BMRF1. Like
pl38, this antigen had excellent reactivities (IgM and IgG)
with most of the sera from patients with IM together with
high diagnostic significance; i.e., none of the ABDs proved
to be IgM positive. High levels of anti-p54-IgG in sera from
patients with IM have been observed earlier by a similar
recombinant ELISA (7). The diagnostic significance of pi38
and p54 has also been substantiated previously in Western
blot experiments with recombinant and natural antigens and
a panel of sera from patients with IM (15).
Although piS0 (BcLF1) is the major viral capsid compo-
nent, gp125 (BALF4) seems to form the dominant antigen of
the VCA complex in current assay systems (19). Our data
show that testing for IgM antibodies with the recombinant
piS0 ELISA may support the diagnosis of IM. However,
despite high concentrations of piS0 in the coating solution,
reactions were usually weak. Moreover, no correlation was
found between p150-IgG and results of standard VCA-IgG
testing.
Because intact piS0 obtained from virus-producing cells,
likewise, showed a restricted seroreactivity, one must as-
sume that other highly sensitive and, perhaps, conforma-
tional epitopes are the diagnostically relevant epitopes on
native pl50 or that other components of the VCA complex
are essential for serodiagnosis.
Excellent sensitivity and high diagnostic significance were
obtained with the EBNA-1 (BKRF1)-specific p72-IgG assay.
Considering the low antigen concentration used in the assay
(Table 1) and taking into account the strong reactivities of
sera from individuals with past EBV infections, this antigen
is the most reactive one among the recombinant EBV
antigens that we studied. It must be emphasized, however,
that the sensitivity, and, hence, the diagnostic significance of
the p72-ELISA, depends entirely on the antigen concentra-
tion that is used for coating. From ELISA series with
increased concentrations of p72, as well as from Western
and dot blot assays, it became evident that conditions can be
established that reveal EBNA-1-IgM antibodies in almost all
serum specimens from patients with IM (data not shown).
The antigen concentration selected for use in this study was
suitable for the assay of IgG antibodies with regard to
differentiation between early and past infections. This is
facilitated by the well-known delayed appearance of EBNA-
1-IgG in the course of a primary EBV infection (9). The
strong reactivity of the p72-IgG that we observed by ELISA
was in full agreement with those in earlier studies of the
highly immunogenic properties of the carboxy-terminal do-
main of p72. On this basis, an ELISA method has been
developed which proved to be 100-fold more sensitive than
ACIF (17).
A further advantage of the recombinant p72 might arise
from deletion of the Gly-Ala copolymer from its amino acid
sequence. This structural part of EBNA-1 was shown to
react with rheumatoid antibodies as well as with autoanti-
bodies in sera from patients with IM (21, 23). Furthermore,
it has been suggested that the Gly-Ala copolymer of
EBNA-1, together with cellular proteins with similar struc-
tures, are the target for anti-rheumatoid arthritis nuclear
antigen antibodies (23). In view of the results presented in
those reports, we assume that omission of the putative
cross-reacting epitopes in the amino-terminal half of p72
added substantially to the specificity of our test system.
On the basis of the results of this study, the following
conclusions can be drawn. The most useful markers in the
diagnosis of IM caused by EBV are IgM antibodies p54,
p54-p138-p150-UgM
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FIG. 2. Hypothetical combination of antigens by reevaluation of
the results presented in Fig. 1 for a set of three hypothetical ELISAs
combining IgM antibodies to p54, pl38, and piS0; IgG antibodies to
p54 and pl38; as well as IgG antibodies to p72. Sera were from
ABDs (O) and patients with IM (a). See legend to Fig. 1 for
definitions of neg, equiv, and pos.
pl38, and p50. Additional positive markers for recent or
ongoing IM can be IgG antibodies to p54 and pl38. Anti-
p72-IgG is typically negative in the early phase of EBV
infections. If it is positive, however, it is a potent indicator of
past exposure to the virus. Judged on this basis, the ELISA
results led to a laboratory diagnosis for the individual serum
specimens from patients with IM which proved to be com-
parable to or even better than the diagnosis we obtained by
standard IF and IP EBV serology (see column labeled R in
Table 2).
Despite their obvious discriminative diagnostic powers,
the multiple individual ELISAs, in their present form, are
not suited for routine laboratory diagnosis of EBV infec-
tions. In agreement with the conclusions presented above,
however, it seems to be possible to reduce the number of
necessary tests per serum specimen by assaying simulta-
neously for anti-p54-, anti-p138, and anti-pl50-IgM, by com-
bining p54 and pl38 in a second assay for IgG antibodies,
and, finally, by testing for anti-p72-IgG. When the results
shown in Fig. 1 were reevaluated by using the aforemen-
tioned hypothetical combination of antigens, the data pre-
sented in Fig. 2 evolved. It is highly suggestive of the
possibility that a rapid, reliable, and discriminative ELISA
system can be established for the specific diagnosis of acute
EBV infection and will be tested under routine conditions in
the near future.
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